HeartBeam Announces Public Offering to Fund Cardiac Technology Commercialization and AI Development

HeartBeam Inc. (NASDAQ: BEAT) announced it is commencing an underwritten public offering of shares of its common stock or common stock equivalents, with all securities to be offered by the company and the final size and terms subject to market conditions. The company said it intends to use net proceeds from the offering to advance commercialization of its FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection initiatives, enhance its AI capabilities and support working capital and general corporate purposes. This financial move represents a critical step in bringing innovative cardiac monitoring technology to broader markets while investing in artificial intelligence applications that could transform how heart conditions are detected and managed.

The importance of this announcement lies in its potential to accelerate the availability of portable cardiac diagnostic tools that operate outside traditional medical facilities. HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management.

The company's technology has received significant regulatory validation, with HeartBeam's 3D ECG technology receiving FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement, providing intellectual property protection for its innovations. The cleared indications for use of the HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment can be reviewed at https://www.heartbeam.com/indications for details on the intended use of its technology.

This public offering comes at a pivotal moment for cardiac care technology, as healthcare systems increasingly seek solutions that enable remote patient monitoring and early intervention. The funding will support not only commercialization efforts but also the enhancement of AI capabilities, suggesting HeartBeam aims to integrate machine learning algorithms with its hardware platform to improve diagnostic accuracy and predictive capabilities. The extended-wear patch development mentioned in the announcement indicates a move toward continuous monitoring solutions that could detect heart attacks before they become critical emergencies.

Titan Partners, a division of American Capital Partners, will act as sole bookrunner for the offering. The financial markets will be watching closely as HeartBeam seeks to capitalize on growing investor interest in medical technology companies addressing cardiovascular disease, which remains a leading cause of death globally. The success of this offering could determine how quickly HeartBeam's technology reaches patients and healthcare providers, potentially establishing new standards for cardiac monitoring outside hospital settings. For investors seeking additional information about the company, the latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT.